XTX Topco’s Contineum Therapeutics CTNM Stock Holding History

XTX Topco’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$498K	Sell	30,356 -5,490	-15%	-$72K	0.01%	2464
2026 Q1	$468K	Buy	+35,846	New	+$481K	0.01%	2107

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

XTX Topco's CTNM Position: Q2 2026 in Review

XTX Topco reduced its Contineum Therapeutics (CTNM) stake by 15% in Q2 2026, selling an estimated $72K and leaving 30,356 shares worth $498K. The position accounts for 0.01% of the portfolio, ranked #2464.

XTX Topco first reported a position in CTNM in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

XTX Topco held 30,356 shares of Contineum Therapeutics worth $498K as of Q2 2026.
XTX Topco sold 5,490 Contineum Therapeutics shares in Q2 2026, an estimated $72K.
Contineum Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2464 holding.
XTX Topco first reported a position in Contineum Therapeutics in Q1 2026 and has held it in 2 quarters since.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.